within Pharmacolibrary.Drugs.ATC.C;

model C10BA08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.14,
    Cl             = 0.010416666666666666,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.381,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.243,
    k12             = 730,
    k21             = 730
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10BA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Atorvastatin and omega-3 fatty acids (ATC code C10BA08) is a combination medication used to treat dyslipidemia and reduce cardiovascular risk. Atorvastatin is a statin that lowers cholesterol by inhibiting HMG-CoA reductase, while omega-3 fatty acids (primarily EPA and DHA) help reduce triglyceride levels. The combination is used for lipid management and is approved in some countries for this purpose.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models are available specifically for the fixed-dose combination of atorvastatin and omega-3 fatty acids. The following estimates are based on typical pharmacokinetic values for orally administered atorvastatin and omega-3 fatty acids in healthy adults.</p><h4>References</h4><ol><li><p>Kim, JH, et al., &amp; Hong, JH (2022). Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers. <i>Pharmaceuticals (Basel, Switzerland)</i> 15(8) –. DOI:<a href=\"https://doi.org/10.3390/ph15080962\">10.3390/ph15080962</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36015110/\">https://pubmed.ncbi.nlm.nih.gov/36015110</a></p></li><li><p>Braeckman, RA, et al., &amp; Soni, PN (2015). Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. <i>Clinical drug investigation</i> 35(1) 45–51. DOI:<a href=\"https://doi.org/10.1007/s40261-014-0252-8\">10.1007/s40261-014-0252-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25471740/\">https://pubmed.ncbi.nlm.nih.gov/25471740</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10BA08;
